$5.0 Million Bought-Deal Public Offering and $1.0 Million Private Placement - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S....

Focus on Diagnostics and Controls for Anti-Microbial Resistant Infections MISSISSAUGA, CANADA and EVELEIGH, AUSTRALIA April 26, 2021 –...

An Initial Order From Government Of Ontario Procurement Authorities MISSISSAUGA, April 23, 2021 – Microbix Biosystems Inc. (TSX: MBX,...

Virtual Healthcare Investor Conference on April 20 & 21 MISSISSAUGA, April 19, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB:...

MISSISSAUGA, March 31, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF)( “Microbix®” or the Company”), a life sciences innovator...

Focus on Supporting Canadian Labs with Variant-related Assays and QAPs MISSISSAUGA & TORONTO, March 15, 2021 – Microbix Biosystems...

REDxFLOQ SARS-CoV-2 Antigen as IVD Controls in Canada, the EU, and the U.S. MISSISSAUGA, March 11, 2021 – Microbix Biosystems Inc. (TSX:...

Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, February 18, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB:...

Oneworld Accuracy as a Non-Exclusive Distributor for Africa and Other Territories MISSISSAUGA, February 16, 2021 – Microbix Biosystems...

Record Q1 Sales, With Nearly 3,600% Year-Over-Year QAPs Growth MISSISSAUGA, February 11, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB:...

Initial Production of 50,000 Vials Entirely Sold MISSISSAUGA, February 9, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF,...

Initial Capacity of 50,000 Vials/Week under Health Canada Regulation MISSISSAUGA, January 28, 2021 – Microbix Biosystems Inc. (TSX: MBX,...